TIGAR and cervical carcinoma: The scope of the present study has been to determine whether inhibiting expression of the TIGAR protein-a p53-regulated glycolytic enzyme and antioxidant effector [19,20,46], could hypersensitize hrHPV-transformed cervical carcinoma cells to cytotoxicity induced by chemotherapy drugs (i.e., cisplatin, etoposide, doxorubicin, and 4-hydroxycyclophosphamide) that cause oxidative stress and DNA-damage [63,64,72,73,86,87].